Skip to main content
Equibles
KYNB logo

KYNB · Kyntra Bio, Inc. · Webcasts, Transcripts & Audio

Track KYNB — free

Use KYNB with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research KYNB.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$5.49 +0.21 (+3.98%)
Rebalance outlook locked
Market Cap
$21.38M
Shares
4.05M
Volume · Oct 20 13.55K Avg daily vol (3M) 19.56K

Kyntra Bio, Inc. Webcasts

Earnings calls, investor updates, investor days and conferences for Kyntra Bio, Inc. (KYNB), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.

Pull transcripts and briefs through the earnings call transcript API or MCP → Add these events to your calendar (.ics)
Conference
Investor event
2026-09-15
Kyntra Bio, Inc. (KYNB) September 15, 2026 Conference
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q2
2026-08-13
Kyntra Bio, Inc. (KYNB) Q2 2026 Earnings Call Transcript
Confident tone FG3246 / FG3180 CD46 ADC program in mCRPC Roxadustat in lower-risk MDS Companion PET imaging and patient selection biomarker
Revenue
−$1.47M
▼ 209.3% YoY
Diluted EPS
$2.96
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY26 · Q1
2026-05-11
Kyntra Bio, Inc. (KYNB) Q1 2026 Earnings Call Transcript
Positive tone FG-3246 ADC program in mCRPC Roxadustat in lower-risk MDS Phase II monotherapy dose optimization trial
Revenue
$3.74M
▲ 36.5% YoY
Diluted EPS
$-3.76
▼ 427% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-03-16
Kyntra Bio, Inc. (KYNB) Q4 2025 Earnings Call Transcript
Positive tone FG-3246 / FG-3180 in mCRPC IST combination data (FG-3246 + enzalutamide) Companion diagnostic / PET imaging strategy
Revenue
$1.28M*
▼ 59.3% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-11-10
Kyntra Bio, Inc. (KYNB) Q3 2025 Earnings Call Transcript
Positive tone Roxadustat in lower-risk MDS CD46 vs PSMA target differentiation and competition Sale of FibroGen China to AstraZeneca
Revenue
$1.08M
▲ 774.8% YoY
Diluted EPS
$49.61
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-11
Kyntra Bio, Inc. (KYNB) Q2 2025 Earnings Call Transcript
Positive tone FG-3246 and FG-3180 in mCRPC Roxadustat for lower-risk MDS Sale of FibroGen China to AstraZeneca
Revenue
$1.35M
▲ 35.1% YoY
Diluted EPS
$-1.88
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-12
Kyntra Bio, Inc. (KYNB) Q1 2025 Earnings Call Transcript
Confident tone FG-3246 ADC Program in mCRPC FG-3180 PET Imaging Agent Roxadustat in MDS (Lower-Risk Myelodysplastic Syndromes)
Revenue
$2.74M
▼ 89.2% YoY
Diluted EPS
$1.15
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-02-20
Kyntra Bio, Inc. (KYNB) Q4 2024 Earnings Call
Revenue
$3.14M*
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-11-12
Kyntra Bio, Inc. (KYNB) Q3 2024 Earnings Call
Revenue
$123,000
▼ 99.7% YoY
Diluted EPS
$-4.25
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-06
Kyntra Bio, Inc. (KYNB) Q2 2024 Earnings Call
Revenue
$998,000
▼ 97.7% YoY
Diluted EPS
$-3.89
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-05-06
Kyntra Bio, Inc. (KYNB) Q1 2024 Earnings Call
Revenue
$25.36M
▼ 29.9% YoY
Diluted EPS
$-8.25
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2024-02-26
Kyntra Bio, Inc. (KYNB) Q4 2023 Earnings Call
Revenue
−$73.81M*
▼ 314.8% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-11-06
Kyntra Bio, Inc. (KYNB) Q3 2023 Earnings Call
Revenue
$40.13M
▲ 155.1% YoY
Diluted EPS
$-16.25
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q2
2023-08-07
Kyntra Bio, Inc. (KYNB) Q2 2023 Earnings Call
Revenue
$44.32M
▲ 48.7% YoY
Diluted EPS
$-22.50
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-05-08
Kyntra Bio, Inc. (KYNB) Q1 2023 Earnings Call
Revenue
$36.16M
▼ 40.6% YoY
Diluted EPS
$-20.25
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q4
2023-02-27
Kyntra Bio, Inc. (KYNB) Q4 2022 Earnings Call
Revenue
$34.37M*
▲ 107.7% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY22 · Q3
2022-11-07
Kyntra Bio, Inc. (KYNB) Q3 2022 Earnings Call
Revenue
$15.73M
▼ 89.9% YoY
Diluted EPS
$-24.50
▼ 281.5% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q2
2022-08-08
Kyntra Bio, Inc. (KYNB) Q2 2022 Earnings Call
Revenue
$29.81M
▲ 22.3% YoY
Diluted EPS
$-19.50
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-05-09
Kyntra Bio, Inc. (KYNB) Q1 2022 Earnings Call
Revenue
$60.83M
▲ 58.3% YoY
Diluted EPS
$-17.00
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-02-28
Kyntra Bio, Inc. (KYNB) Q4 2021 Earnings Call
Revenue
$16.54M*
▼ 74.5% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q3
2021-11-09
Kyntra Bio, Inc. (KYNB) Q3 2021 Earnings Call
Revenue
$155.97M
▲ 254.2% YoY
Diluted EPS
$13.50
▲ 54.3% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q2
2021-08-09
Kyntra Bio, Inc. (KYNB) Q2 2021 Earnings Call
Revenue
$24.36M
▼ 43.2% YoY
Diluted EPS
$-36.25
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q1
2021-05-10
Kyntra Bio, Inc. (KYNB) Q1 2021 Earnings Call
Revenue
$38.43M
▲ 57.5% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q4
2021-03-01
Kyntra Bio, Inc. (KYNB) Q4 2020 Earnings Call
Revenue
$65.00M*
▲ 715.1% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY20 · Q3
2020-11-05
Kyntra Bio, Inc. (KYNB) Q3 2020 Earnings Call
Revenue
$44.03M
▲ 32.7% YoY
Diluted EPS
$8.75
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q2
2020-08-06
Kyntra Bio, Inc. (KYNB) Q2 2020 Earnings Call
Revenue
$42.89M
▼ 77.6% YoY
Diluted EPS
$-23.75
▼ 175.4% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q1
2020-05-07
Kyntra Bio, Inc. (KYNB) Q1 2020 Earnings Call
Revenue
$24.40M
▲ 2.3% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY19 · Q4
2020-03-02
Kyntra Bio, Inc. (KYNB) Q4 2019 Earnings Call
Revenue
$7.97M*
▼ 92.6% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Showing 1–28 of 28 webcasts
Key facts CIK 921299 CUSIP 31572Q881 13F (30d) 1 filings 1 filers Visit website Investor relations